May 25, 2006 – Encysive responded to the approvable letter it received for Thelin, without needing additional trials; Genentech requested FDA approval of Avastin as a first-line therapy for breast cancer; Allergan received European approval of Ganfort as a glaucoma therapy; Angiotech Pharma will acquire Quill Medical for $40 million; SciClone said Zadaxin failed a Phase III trial against hepatitis C; Adams Respiratory bought Delsym, a prescription 12-hour cough syrup, from UCB for $122 million; New River Pharma presented data showing its attention deficit disorder drug was effective in children between the ages of 6 and 12; Trinity Biotech will buy the coagulation product line from bioMerieux for $51.9 million; and Volcano, which makes intravascular ultrasound imaging devices, set terms for its IPO. The Centient Biotech 200™ moved up 66 points to 3642.10, a rise of 1.84%. More details...
